1. Home
  2. DFIN vs WVE Comparison

DFIN vs WVE Comparison

Compare DFIN & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFIN
  • WVE
  • Stock Information
  • Founded
  • DFIN 1983
  • WVE 2012
  • Country
  • DFIN United States
  • WVE Singapore
  • Employees
  • DFIN N/A
  • WVE N/A
  • Industry
  • DFIN Other Consumer Services
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFIN Consumer Discretionary
  • WVE Health Care
  • Exchange
  • DFIN Nasdaq
  • WVE Nasdaq
  • Market Cap
  • DFIN 1.4B
  • WVE 1.7B
  • IPO Year
  • DFIN N/A
  • WVE 2015
  • Fundamental
  • Price
  • DFIN $42.95
  • WVE $10.52
  • Analyst Decision
  • DFIN Strong Buy
  • WVE Strong Buy
  • Analyst Count
  • DFIN 3
  • WVE 11
  • Target Price
  • DFIN $71.33
  • WVE $22.00
  • AVG Volume (30 Days)
  • DFIN 397.9K
  • WVE 1.0M
  • Earning Date
  • DFIN 04-30-2025
  • WVE 03-04-2025
  • Dividend Yield
  • DFIN N/A
  • WVE N/A
  • EPS Growth
  • DFIN 13.75
  • WVE N/A
  • EPS
  • DFIN 3.06
  • WVE N/A
  • Revenue
  • DFIN $781,900,000.00
  • WVE $108,302,000.00
  • Revenue This Year
  • DFIN $4.59
  • WVE N/A
  • Revenue Next Year
  • DFIN $4.40
  • WVE $33.28
  • P/E Ratio
  • DFIN $14.43
  • WVE N/A
  • Revenue Growth
  • DFIN N/A
  • WVE N/A
  • 52 Week Low
  • DFIN $44.15
  • WVE $4.25
  • 52 Week High
  • DFIN $71.01
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • DFIN 25.76
  • WVE 50.22
  • Support Level
  • DFIN $45.09
  • WVE $8.57
  • Resistance Level
  • DFIN $47.45
  • WVE $11.71
  • Average True Range (ATR)
  • DFIN 1.62
  • WVE 0.86
  • MACD
  • DFIN -0.23
  • WVE 0.04
  • Stochastic Oscillator
  • DFIN 0.06
  • WVE 71.34

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: